Medically reviewed by Dr. Wendi J. Lundquist, DO, Physical Medicine & Rehabilitation
A switch assumes the first compound was doing something measurable, or should have been. In healthy adults, no product in this category has established benefit for the goals people usually bring to it, so the first question is not what to move to. It is whether continuing at all is justified by anything that was actually measured.
Establish what the first prescription was supposed to achieve
Before any transition is discussed, three things should be written down: what the target was, what was measured at baseline, and what those measurements show now. If the target was never stated in a form that could be checked, a switch cannot improve on it. Trading one unmeasured prescription for another produces a new invoice and no new information.
Where a diagnosis does exist, the frame is different. Guideline recommendations for adult growth hormone deficiency describe assessment, treatment, and follow-up in a defined sequence, and changes are made against test results rather than impressions. That structure is what the wellness version of this category tends to lack.
Which reasons for switching hold up
| Reason given | Question that tests it | How it usually resolves |
|---|---|---|
| Nothing happened | What was measured, and did the axis move at all? | Often a reason to stop, not to substitute |
| Side effects | Are they dose-related, and was reducing stimulation tried? | Shared class effects tend to follow a switch |
| A newer compound is available | What human outcome data supports it? | Usually none exists for either compound |
| Cost | Which components changed, and does the new price include labs? | Legitimate, if the comparison is complete |
| Supply interruption | Is this pharmacy-specific or product-wide? | Legitimate, and worth planning around |
| Provider recommended it | On what finding, and what will confirm it worked? | Depends entirely on the answer |
Only two of those reasons survive scrutiny on their own. The rest depend on evidence that generally has not been gathered.
The contrast with GLP-1 therapy is worth noting. There, moving between approved drugs like semaglutide and tirzepatide is a genuine clinical decision with dosing data behind it, and providers such as Ro, Hims and Hers, and Henry Meds walk patients through the change. Guidance like the HealthRX explainer on switching GLP-1 medications rests on approved labeling that growth hormone peptides do not have, which is why a peptide switch cannot lean on the same kind of evidence.
Side effects rarely disappear across a switch
Swelling, joint aches, hand numbness, and drifting glucose come from stimulating the same axis, so moving between compounds that both raise growth hormone tends to carry the complaint along. A review of growth hormone secretagogues in humans described the class as broadly tolerated in short studies while singling out reduced insulin sensitivity and higher blood glucose as the recurring concern across agents.
Moving between mechanism families changes the receptor but not the hormone being raised. The exception worth taking seriously is when a specific compound carries its own documented signal. FDA has flagged ibutamoren over a potential congestive heart failure signal from a terminated trial, and has described serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction. Leaving a compound with a named signal is a different decision from shopping for a gentler version of the same effect.
Combining is not the answer to a disappointing result
The common suggestion when one compound underdelivers is to add another. There is no human outcome evidence supporting combinations in healthy adults. The frequently cited work pairing a releasing hormone with a releasing peptide was a short physiology study in older volunteers that measured hormone secretion, not body composition, strength, or any clinical endpoint. Similarly, the published study of CJC-1295 in healthy adults tracked hormone and IGF-I concentrations over several weeks and drew no conclusions about outcomes.
Stacking questions also tend to move a conversation away from the one that matters, which is whether the axis needs stimulating at all. A prescriber who answers a combination question with a measurement plan is more useful than one who answers it with a product list.
Records that should travel with you
Any transition, especially one that also changes provider, should carry a paper trail. That means baseline and most recent laboratory results, a record of what was prescribed and for how long, documentation of any adverse effects and what was done about them, and the pharmacy that prepared the medication.
Continuity is where cash-pay telehealth varies most, because records are often held inside a platform rather than shared automatically. Providers such as Ways2Well and Defy Medical operate their own clinical files, and platforms including FormBlends publish program terms that are worth reading before a transfer rather than during one. Asking how records are released, and in what format, avoids restarting an evaluation that has already been paid for once.
Stopping deserves the same consideration as switching
Growth hormone secretagogues are not treating an emergency in a healthy adult, and there is no withdrawal syndrome that makes stopping hazardous. When a course produced nothing measurable, ending it is a legitimate outcome rather than a failure to find the right compound.
That option is easy to lose sight of inside a recurring subscription, where the default action is renewal. Setting a stopping rule at the outset, tied to a specific measurement and a specific date, keeps the decision in view.
Sourcing questions when the provider changes
Ask which pharmacy will prepare the new prescription and whether it is a 503A compounder filling individual prescriptions or a 503B outsourcing facility, since the two operate under different federal requirements. Ask whether the preparation is the same concentration and formulation as before, because compounded products differ between pharmacies. Ask what documentation accompanies the shipment.
One point does not change with any switch. Growth hormone, its releasing factors, and its secretagogues are prohibited at all times under the World Anti-Doping Code, so an athlete in a testing pool gains nothing by moving between compounds in this category.
Frequently asked questions
Is a washout period needed between compounds?
No validated protocol exists, because the comparative studies that would establish one have not been done. What is reasonable is a gap long enough to draw meaningful laboratory values, so that any change afterward can be attributed rather than guessed at.
Will switching from an injectable to an oral compound reduce side effects?
Not predictably. The oral secretagogue MK-677 has its own profile, including increased appetite, weight gain, transient swelling, and reduced insulin sensitivity, and FDA has flagged it over a congestive heart failure signal. It removes injections, not class effects.
Can a prescriber transfer an existing compounded prescription?
Practice varies. A new prescriber will usually want their own evaluation and current laboratory values before writing anything, and a compounded preparation is specific to the pharmacy that makes it. Expect a fresh assessment rather than a direct handover.
Is tesamorelin a step up from a compounded peptide?
It is the only approved product in the category, but its approval covers reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Its labeling states it is not indicated for weight loss management, so it is not an upgrade path for general use.
How long should a trial run before deciding?
That should be agreed in advance with a defined measurement, not discovered later. Setting the review date and the specific value being watched at the start is what makes stopping, continuing, or switching a decision rather than a habit.
